Literature DB >> 15645285

Unusual presentation of congenital disorder of glycosylation type 1a: congenital persistent thrombocytopenia, hypertrophic cardiomyopathy and hydrops-like aspect due to marked peripheral oedema.

Vera Noelle1, Matthias Knuepfer, Ferdinand Pulzer, Volker Schuster, Werner Siekmeyer, Gert Matthijs, Christoph Vogtmann.   

Abstract

UNLABELLED: Of the congenital disorder of glycosylation (CDG) syndromes, type 1a is the most common. CDG 1a is a multisystem disorder with a wide clinical spectrum. We report on a term newborn with a severe and fatal clinical course of CDG 1a syndrome. Skin fibroblasts showed a reduced activity of phosphomannomutase 2 (PMM2) and mutation analysis revealed a compound heterozygous PMM2gene mutation (F119L/F157S). Presenting features at birth were hypertrophic non-obstructive cardiomyopathy, "orange-peel" skin, inverted nipples and a hydrops-like aspect due to marked peripheral oedema. Suspected hydrops fetalis was not confirmed due to lack of ascites and pleural effusions. Striking clinical problems were therapy-resistant arterial hypertension, recurrent pericardial and pleural effusions and feeding difficulties with failure to thrive. Persistent congenital thrombocytopenia and hyperferritinaemia in the absence of infection were noted. Bone marrow cytology revealed a macrophage activation of unknown aetiology.
CONCLUSION: Congenital thrombocytopenia, unspecific macrophage activation and a hydrops-like aspect without a real hydrops fetalis broaden the already wide phenotypic spectrum of congenital disorder of glycosylation syndrome type 1a.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15645285     DOI: 10.1007/s00431-004-1611-x

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  12 in total

1.  PMM2 mutation spectrum, including 10 novel mutations, in a large CDG type 1A family material with a focus on Scandinavian families.

Authors:  C Bjursell; A Erlandson; M Nordling; S Nilsson; J Wahlström; H Stibler; B Kristiansson; T Martinsson
Journal:  Hum Mutat       Date:  2000-11       Impact factor: 4.878

2.  Biochemical and molecular studies in 26 Spanish patients with congenital disorder of glycosylation type Ia.

Authors:  P Briones; M A Vilaseca; E Schollen; I Ferrer; M Maties; C Busquets; R Artuch; L Gort; M Marco; E van Schaftingen; G Matthijs; J Jaeken; A Chabás
Journal:  J Inherit Metab Dis       Date:  2002-12       Impact factor: 4.982

3.  Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders.

Authors:  S Sawhney; P Woo; K J Murray
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

4.  Recurrent nonimmune hydrops fetalis associated with carbohydrate-deficient glycoprotein syndrome.

Authors:  T J de Koning; M Toet; L Dorland; L S de Vries; I E van den Berg; M Duran; B T Poll-The
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

Review 5.  The carbohydrate-deficient glycoprotein syndromes: an overview.

Authors:  J Jaeken; H Carchon
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia).

Authors:  G Matthijs; E Schollen; C Bjursell; A Erlandson; H Freeze; F Imtiaz; S Kjaergaard; T Martinsson; M Schwartz; N Seta; S Vuillaumier-Barrot; V Westphal; B Winchester
Journal:  Hum Mutat       Date:  2000-11       Impact factor: 4.878

7.  Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A.

Authors:  G Matthijs; E Schollen; E Van Schaftingen; J J Cassiman; J Jaeken
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

8.  Carbohydrate-deficient glycoprotein syndrome type 1 with profound thrombocytopenia and normal phosphomannomutase and phosphomannose isomerase activities.

Authors:  M J Acarregui; T N George; W J Rhead
Journal:  J Pediatr       Date:  1998-11       Impact factor: 4.406

Review 9.  Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.

Authors:  T Marquardt; J Denecke
Journal:  Eur J Pediatr       Date:  2003-03-15       Impact factor: 3.183

10.  Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I.

Authors:  E Van Schaftingen; J Jaeken
Journal:  FEBS Lett       Date:  1995-12-27       Impact factor: 4.124

View more
  12 in total

1.  Congenital disorder of glycosylation type Ia presenting with hydrops fetalis.

Authors:  J M van de Kamp; D J Lefeber; G J G Ruijter; S J Steggerda; N S den Hollander; S M Willems; G Matthijs; B J H M Poorthuis; R A Wevers
Journal:  J Med Genet       Date:  2006-12-08       Impact factor: 6.318

2.  Early fatal course in siblings with CDG-Ia (caused by two novel mutations in the PMM2 gene): clinical, molecular and autopsy findings.

Authors:  Donald Wurm; Andrea Hänsgen; Yoo-Jin Kim; Angelika Lindinger; Ali Baghai; Ludwig Gortner
Journal:  Eur J Pediatr       Date:  2006-08-29       Impact factor: 3.183

Review 3.  Recognizable phenotypes in CDG.

Authors:  Carlos R Ferreira; Ruqaia Altassan; Dorinda Marques-Da-Silva; Rita Francisco; Jaak Jaeken; Eva Morava
Journal:  J Inherit Metab Dis       Date:  2018-04-13       Impact factor: 4.982

Review 4.  Infant with cardiomyopathy: When to suspect inborn errors of metabolism?

Authors:  Stephanie L Byers; Can Ficicioglu
Journal:  World J Cardiol       Date:  2014-11-26

Review 5.  Cardiac complications of congenital disorders of glycosylation (CDG): a systematic review of the literature.

Authors:  D Marques-da-Silva; R Francisco; D Webster; V Dos Reis Ferreira; J Jaeken; T Pulinilkunnil
Journal:  J Inherit Metab Dis       Date:  2017-07-19       Impact factor: 4.982

6.  Congenital disorders of glycosylation with neonatal presentation.

Authors:  Catarina Resende; Carmen Carvalho; Artur Alegria; Dulce Oliveira; Dulce Quelhas; Anabela Bandeira; Elisa Proença
Journal:  BMJ Case Rep       Date:  2014-04-16

7.  Cystic kidney diseases associated with mutations in phosphomannomutase 2 promotor: a large spectrum of phenotypes.

Authors:  Guillaume Dorval; Cécile Jeanpierre; Vincent Morinière; Carole Tournant; Bettina Bessières; Tania Attié-Bittach; Jeanne Amiel; Emmanuel Spaggari; Yves Ville; Elodie Merieau; Marie-Claire Gubler; Sophie Saunier; Laurence Heidet
Journal:  Pediatr Nephrol       Date:  2021-02-13       Impact factor: 3.714

Review 8.  Immunological aspects of congenital disorders of glycosylation (CDG): a review.

Authors:  Maria Monticelli; Tiago Ferro; Jaak Jaeken; Vanessa Dos Reis Ferreira; Paula A Videira
Journal:  J Inherit Metab Dis       Date:  2016-07-08       Impact factor: 4.750

9.  Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation.

Authors:  Dirk J Lefeber; Arjan P M de Brouwer; Eva Morava; Moniek Riemersma; Janneke H M Schuurs-Hoeijmakers; Birgit Absmanner; Kiek Verrijp; Willem M R van den Akker; Karin Huijben; Gerry Steenbergen; Jeroen van Reeuwijk; Adam Jozwiak; Nili Zucker; Avraham Lorber; Martin Lammens; Carlos Knopf; Hans van Bokhoven; Stephanie Grünewald; Ludwig Lehle; Livia Kapusta; Hanna Mandel; Ron A Wevers
Journal:  PLoS Genet       Date:  2011-12-29       Impact factor: 5.917

Review 10.  PIGO deficiency: palmoplantar keratoderma and novel mutations.

Authors:  Marie-Anne Morren; Jaak Jaeken; Gepke Visser; Isabelle Salles; Chris Van Geet; Ilenia Simeoni; Ernest Turro; Kathleen Freson
Journal:  Orphanet J Rare Dis       Date:  2017-05-25       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.